These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 26169974)
21. C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls. Jacomb I; Stanton C; Vasudevan R; Powell H; O'Donnell M; Lenroot R; Bruggemann J; Balzan R; Galletly C; Liu D; Weickert CS; Weickert TW Front Immunol; 2018; 9():2230. PubMed ID: 30364161 [TBL] [Abstract][Full Text] [Related]
22. Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study. Metcalf SA; Jones PB; Nordstrom T; Timonen M; Mäki P; Miettunen J; Jääskeläinen E; Järvelin MR; Stochl J; Murray GK; Veijola J; Khandaker GM Brain Behav Immun; 2017 Jan; 59():253-259. PubMed ID: 27622678 [TBL] [Abstract][Full Text] [Related]
23. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Harrow M; Jobe TH; Faull RN Psychol Med; 2012 Oct; 42(10):2145-55. PubMed ID: 22340278 [TBL] [Abstract][Full Text] [Related]
24. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia. Stefanović V; Mihajlović G; Nenadović M; Dejanović SD; Borovcanin M; Trajković G Vojnosanit Pregl; 2015 Dec; 72(12):1085-92. PubMed ID: 26898032 [TBL] [Abstract][Full Text] [Related]
25. Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort. Fond G; Sunhary de Verville PL; Richieri R; Etchecopar-Etchart D; Korchia T; Faugere M; Godin O; Schürhoff F; Berna F; Aouizerate B; Capdevielle D; Chereau I; Clauss-Kobayashi J; Coulon N; Dorey JM; Dubertret C; Dubreucq J; Mallet J; Misdrahi D; Passerieux C; Pignon B; Rey R; Urbach M; Leboyer M; Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110335. PubMed ID: 33933539 [TBL] [Abstract][Full Text] [Related]
26. C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Fernandes BS; Steiner J; Molendijk ML; Dodd S; Nardin P; Gonçalves CA; Jacka F; Köhler CA; Karmakar C; Carvalho AF; Berk M Lancet Psychiatry; 2016 Dec; 3(12):1147-1156. PubMed ID: 27838212 [TBL] [Abstract][Full Text] [Related]
27. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Bora E Psychol Med; 2019 Sep; 49(12):1971-1979. PubMed ID: 31284882 [TBL] [Abstract][Full Text] [Related]
28. Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis. Girshkin L; Matheson SL; Shepherd AM; Green MJ Psychoneuroendocrinology; 2014 Nov; 49():187-206. PubMed ID: 25108162 [TBL] [Abstract][Full Text] [Related]
29. Increased annexin-V and decreased TNF-α serum levels in chronic-medicated patients with schizophrenia. Francesconi LP; Ceresér KM; Mascarenhas R; Stertz L; Gama CS; Belmonte-de-Abreu P Neurosci Lett; 2011 Sep; 502(3):143-6. PubMed ID: 21741441 [TBL] [Abstract][Full Text] [Related]
30. Association of Serum Trace Elements with Schizophrenia and Effects of Antipsychotic Treatment. Chen X; Li Y; Zhang T; Yao Y; Shen C; Xue Y Biol Trace Elem Res; 2018 Jan; 181(1):22-30. PubMed ID: 28470477 [TBL] [Abstract][Full Text] [Related]
33. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. Song HT; Sun XY; Zhang L; Zhao L; Guo ZM; Fan HM; Zhong AF; Niu W; Dai YH; Zhang LY; Shi Z; Liu XP; Lu J J Psychiatr Res; 2014 Jul; 54():134-40. PubMed ID: 24694668 [TBL] [Abstract][Full Text] [Related]
34. Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment. Zeng B; Ardekani BA; Tang Y; Zhang T; Zhao S; Cui H; Fan X; Zhuo K; Li C; Xu Y; Goff DC; Wang J Schizophr Res; 2016 Apr; 172(1-3):1-8. PubMed ID: 26852402 [TBL] [Abstract][Full Text] [Related]
35. Birth by cesarean section and schizophrenia: results from the multicenter FACE-SZ data-set. Fond G; Bulzacka E; Boyer L; Llorca PM; Godin O; Brunel L; Andrianarisoa MG; Aouizerate B; Berna F; Capdevielle D; Chereau I; Denizot H; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Le Strat Y; Micoulaud-Franchi JA; Misdrahi D; Rey R; Richieri R; Roger M; Passerieux C; Schandrin A; Urbach M; Vidalhet P; Schürhoff F; Leboyer M; Eur Arch Psychiatry Clin Neurosci; 2017 Sep; 267(6):587-594. PubMed ID: 27349652 [TBL] [Abstract][Full Text] [Related]
36. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Harrow M; Jobe TH; Faull RN Psychol Med; 2014 Oct; 44(14):3007-16. PubMed ID: 25066792 [TBL] [Abstract][Full Text] [Related]
38. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756 [TBL] [Abstract][Full Text] [Related]
39. Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis. Lestra V; Romeo B; Martelli C; Benyamina A; Hamdani N Schizophr Res; 2022 Aug; 246():175-186. PubMed ID: 35785580 [TBL] [Abstract][Full Text] [Related]
40. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia. Borovcanin M; Jovanovic I; Dejanovic SD; Radosavljevic G; Arsenijevic N; Lukic ML Psychoneuroendocrinology; 2015 Jun; 56():143-7. PubMed ID: 25827958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]